SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
Project Partners
Academic Institutions
- Lund University*
- University of Cambridge
- University of Dundee*
- University of Exeter
- University of Gothenburg
- University of Eastern Finland
- University of Oxford
- Università degli Studi di Padova
- Università degli Studi di Pavia
- Università di Pisa
- Università Cattolica del Sacro Cuore, Rome
- University of Turku
- University of Edinburgh
- Università di Firenze
Pharmaceutical companies
*Coordinating and managing participants
AstraZeneca
Lund University
University of Dundee
University of Oxford
University of Gothenburg
University of Edinburgh
Boehringer Ingelheim
Sanofi-Aventis Deutschland GmbH
Helmholtz Zentrum Muenchen
F. Hoffmann-La Roche Ltd
Università di Pisa
Università di Firenze
University of Turku
University of Cambridge
Università degli Studi di Padova
Pfizer
University of Exeter
Instituto di Ricerche Farmacologiche “Mario Negri”, Bergamo
Karolinska Institute
Folkhälsan, Helsinki
The National Institute for Health and Welfare, Finland
Eli Lilly Ltd
Biocomputing Platforms Ltd
Università Cattolica del Sacro Cuore, Rome
Università degli Studi di Pavia
University of Eastern Finland
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.
Related Sites
